DIVI S LABORATORIES Latest Share Price (DIVISLAB)
TODAY IN ONE LINE
DIVISLAB fell 1.6% on average volume, lagging Nifty's 0.1% move.
With a market cap of ₹2.42 L Cr., it trades at a P/E of 83.79. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
DIVI S LABORATORIES flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 13.6% YoY
- ●Consistent GrowthEPS compounded at 12.1% over 3 years
- ●High Capital EfficiencyROCE of 15.8% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 15.6%
- ●Healthy Operating MarginsOPM is structurally strong at 33.3%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 3.4% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 67.6x
- ●Rising Receivables vs SalesReceivables grew 25.5% outpacing sales growth of 19.3%
Latest DIVI S LABORATORIES News
What changed recently?
Recent events, corporate actions, and announcements.
DIVI S LABORATORIES valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for DIVI S LABORATORIES, framed against the sector median so the premium or discount is obvious at a glance.
DIVI S LABORATORIES trades at a P/E of 83.79× and P/B of 14.62×, against the Healthcare sector median P/E of 41.28×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
DIVI S LABORATORIES technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for DIVI S LABORATORIES — derived from the latest tape, not yesterday's close.
DIVI S LABORATORIES last traded at ₹9,100 with an intraday range of ₹9,100–₹9,269 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹9100.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 9550.67 | +450.67 | +4.95% |
| R3 | 9381.67 | +281.67 | +3.10% |
| R2 | 9325.33 | +225.33 | +2.48% |
| R1 | 9212.67 | +112.67 | +1.24% |
| PIVOT | 9156.33 | 56.33 | 0.62% |
| CURRENT | 9100.00 | — | — |
| S1 | 9043.67 | -56.33 | -0.62% |
| S2 | 8987.33 | -112.67 | -1.24% |
| S3 | 8874.67 | -225.33 | -2.48% |
| S4 | 8705.67 | -394.33 | -4.33% |
DIVISLAB is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹9148–₹9269
Trading Below opening range, showing Bearishness
DIVI S LABORATORIES financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for DIVI S LABORATORIES — consolidated or standalone — with margins, YoY growth and key ratios inline.
DIVI S LABORATORIES reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2.42 L Cr. and reported EPS of ₹33.56.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 9,360 | 10,560 ▲ 12.8% |
| Sales Growth YoY %Derived | 19.31% | 12.82% |
| Other Income | 352 | 507 ▲ 44.0% |
| Total Income | 9,712 | 11,067 ▲ 14.0% |
| 3,725 | 4,093 ▲ 9.9% | |
| Gross ProfitDerived | 5,635 | 6,467 ▲ 14.8% |
| Gross Margin %Derived | 60.20% | 61.24% |
| 2,667 | 3,026 ▲ 13.5% | |
| EBITDA (Operating Profit)Derived | 2,968 | 3,441 ▲ 15.9% |
| OPM %Derived | 31.71% | 32.59% |
| 404 | 412 ▲ 2.0% | |
| Profit Before Tax (PBT) | 2,916 | 3,388 ▲ 16.2% |
| 725 | 820 ▲ 13.1% | |
| Effective Tax %Derived | 24.86% | 24.20% |
| Total Profit for Period | 2,191 | 2,568 ▲ 17.2% |
| Net Profit (Owner's PAT)Derived | 2,191 | 2,568 ▲ 17.2% |
| Net Profit Margin %Derived | 23.41% | 24.32% |
| PAT Growth YoY %Derived | 36.94% | 17.21% |
| Earnings Per Share (EPS ₹) | 82.53 | 96.73 ▲ 17.2% |
| Diluted Shares Outstanding (Cr) | 27 | 27 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 3 | 21 ▲ 600.0% |
| Total Expenses (incl. D&A & Interest) | 6,796 | 7,679 ▲ 13.0% |
| Material Cost % of RevenueDerived | 40.82% | 41.46% |
| Employee Cost % of RevenueDerived | 13.28% | 13.66% |
| Other Cost % of RevenueDerived | 15.21% | 15.00% |
| Interest Coverage (x)Derived | 1,283.00x | 129.48x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 3,913 | 4,946 ▲ 26.4% | 5,394 ▲ 9.1% | 6,969 ▲ 29.2% | 8,960 ▲ 28.6% | 7,768 ▼ 13.3% | 7,845 ▲ 1.0% | 9,360 ▲ 19.3% | 10,560 ▲ 12.8% | |
| Sales Growth YoY %Derived | — | 26.41% | 9.06% | 29.20% | 28.56% | -13.31% | 1.00% | 19.31% | 12.82% | |
| Other Income | 113 | 156 ▲ 37.2% | 190 ▲ 21.8% | 63 ▼ 67.0% | 114 ▲ 82.0% | 345 ▲ 202.7% | 339 ▼ 1.6% | 352 ▲ 3.8% | 507 ▲ 44.0% | |
| Total Income | 4,026 | 5,102 ▲ 26.7% | 5,584 ▲ 9.5% | 7,032 ▲ 25.9% | 9,074 ▲ 29.0% | 8,112 ▼ 10.6% | 8,184 ▲ 0.9% | 9,712 ▲ 18.7% | 11,067 ▲ 14.0% | |
1,534 | 1,825 ▲ 19.0% | 2,109 ▲ 15.5% | 2,324 ▲ 10.2% | 2,967 ▲ 27.7% | 3,054 ▲ 2.9% | 3,129 ▲ 2.5% | 3,725 ▲ 19.0% | 4,093 ▲ 9.9% | ||
| Gross ProfitDerived | 2,379 | 3,121 ▲ 31.2% | 3,286 ▲ 5.3% | 4,645 ▲ 41.4% | 5,993 ▲ 29.0% | 4,714 ▼ 21.3% | 4,716 ▲ 0.0% | 5,635 ▲ 19.5% | 6,467 ▲ 14.8% | |
| Gross Margin %Derived | 60.79% | 63.10% | 60.91% | 66.65% | 66.88% | 60.69% | 60.11% | 60.20% | 61.24% | |
1,117 | 1,249 ▲ 11.8% | 1,464 ▲ 17.2% | 1,785 ▲ 22.0% | 2,111 ▲ 18.2% | 2,346 ▲ 11.1% | 2,511 ▲ 7.0% | 2,667 ▲ 6.2% | 3,026 ▲ 13.5% | ||
| EBITDA (Operating Profit)Derived | 1,262 | 1,872 ▲ 48.4% | 1,822 ▼ 2.7% | 2,860 ▲ 57.0% | 3,882 ▲ 35.7% | 2,368 ▼ 39.0% | 2,205 ▼ 6.9% | 2,968 ▲ 34.6% | 3,441 ▲ 15.9% | |
| OPM %Derived | 32.25% | 37.84% | 33.78% | 41.04% | 43.33% | 30.48% | 28.11% | 31.71% | 32.59% | |
144 | 172 ▲ 19.9% | 192 ▲ 11.6% | 256 ▲ 33.3% | 312 ▲ 21.8% | 344 ▲ 10.1% | 381 ▲ 10.8% | 404 ▲ 6.0% | 412 ▲ 2.0% | ||
| Profit Before Tax (PBT) | 1,231 | 1,855 ▲ 50.7% | 1,819 ▼ 1.9% | 2,666 ▲ 46.5% | 3,684 ▲ 38.2% | 2,369 ▼ 35.7% | 2,163 ▼ 8.7% | 2,916 ▲ 34.8% | 3,388 ▲ 16.2% | |
354 | 502 ▲ 41.8% | 443 ▼ 11.8% | 682 ▲ 53.9% | 723 ▲ 6.1% | 545 ▼ 24.6% | 563 ▲ 3.3% | 725 ▲ 28.8% | 820 ▲ 13.1% | ||
| Effective Tax %Derived | 28.78% | 27.08% | 24.34% | 25.57% | 19.63% | 23.02% | 26.03% | 24.86% | 24.20% | |
| Total Profit for Period | 877 | 1,353 ▲ 54.2% | 1,377 ▲ 1.8% | 1,984 ▲ 44.2% | 2,960 ▲ 49.2% | 1,823 ▼ 38.4% | 1,600 ▼ 12.3% | 2,191 ▲ 36.9% | 2,568 ▲ 17.2% | |
| Net Profit (Owner's PAT)Derived | 877 | 1,353 ▲ 54.2% | 1,377 ▲ 1.8% | 1,984 ▲ 44.2% | 2,960 ▲ 49.2% | 1,823 ▼ 38.4% | 1,600 ▼ 12.3% | 2,191 ▲ 36.9% | 2,568 ▲ 17.2% | |
| Net Profit Margin %Derived | 22.41% | 27.35% | 25.52% | 28.47% | 33.04% | 23.47% | 20.40% | 23.41% | 24.32% | |
| PAT Growth YoY %Derived | — | 54.24% | 1.76% | 44.15% | 49.19% | -38.41% | -12.25% | 36.94% | 17.21% | |
| Earnings Per Share (EPS ₹) | 33.04 | 50.96 ▲ 54.2% | 51.85 ▲ 1.7% | 74.75 ▲ 44.2% | 111.52 ▲ 49.2% | 68.69 ▼ 38.4% | 60.27 ▼ 12.3% | 82.53 ▲ 36.9% | 96.73 ▲ 17.2% | |
| Diluted Shares Outstanding (Cr) | 27 | 27 ▲ 0.0% | 27 ▲ 0.0% | 27 ▲ 0.0% | 27 ▲ 0.0% | 27 ▲ 0.0% | 27 ▲ 0.0% | 27 ▲ 0.0% | 27 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 10 | -0 ▼ 103.5% | 0 ▲ 200.0% | 0 ▲ 14.3% | 4 ▲ 915.0% | 12 ▲ 194.1% | — ▼ 100.0% | 3 | 21 ▲ 600.0% | |
| Total Expenses (incl. D&A & Interest) | 2,795 | 3,247 ▲ 16.2% | 3,765 ▲ 15.9% | 4,366 ▲ 16.0% | 5,390 ▲ 23.5% | 5,744 ▲ 6.6% | 6,021 ▲ 4.8% | 6,796 ▲ 12.9% | 7,679 ▲ 13.0% | |
| Material Cost % of RevenueDerived | 39.07% | 42.53% | 40.75% | 34.40% | 38.80% | 38.73% | 41.20% | 40.82% | 41.46% | |
| Employee Cost % of RevenueDerived | 11.66% | 10.96% | 11.51% | 11.85% | 10.56% | 12.55% | 13.95% | 13.28% | 13.66% | |
| Other Cost % of RevenueDerived | 16.89% | 14.29% | 15.62% | 13.77% | 13.00% | 17.65% | 18.06% | 15.21% | 15.00% | |
| Interest Coverage (x)Derived | 841.52x | 486.55x | 268.19x | 2,993.51x | 4,463.04x | 3,021.85x | 609.00x | 1,283.00x | 129.48x |
DIVI S LABORATORIES segment analysis : revenue and profit mix.
Disclosed business segments at DIVI S LABORATORIES with their share of revenue and profit, switchable between consolidated and standalone reporting.
DIVI S LABORATORIES discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for DIVI S LABORATORIES.
Our AI distills the core fundamental drivers supporting DIVI S LABORATORIES, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
DIVI S LABORATORIES's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 28.20% substantially outpaces pharmaceutical peer averages significantly.
Net profit margin 24.36% TTM demonstrates exceptional pricing power and operational efficiency.
ROCE 15.79% and ROE 15.60% reflect strong capital deployment and consistent returns.
Debt-to-equity 0.0000 with ₹0.00 LCr total debt ensures fortress balance sheet strength.
Latest quarterly EPS grew 13.40% YoY, demonstrating strong earnings expansion momentum.
Key Risks.
P/E ratio 67.63x significantly exceeds peer median, indicating premium valuation concerns.
EV/EBITDA 46.33x substantially above peer median suggests overvaluation relative to earnings.
Dividend yield 0.33% offers minimal income for yield-focused investors seeking returns.
Price-to-book 14.65x trades at significant premium relative to peer benchmarks.
52-week return 4.65% near range top limits near-term upside despite strong fundamentals.
Flip Conditions.
Valuation risk. a P/E above 109 (~2.6× the sector multiple of 41.3) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 11% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.17%.
DIVI S LABORATORIES peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — DIVI S LABORATORIES is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
DIVI S LABORATORIES chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for DIVI S LABORATORIES — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
DIVI S LABORATORIES delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for DIVI S LABORATORIES over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in DIVI S LABORATORIES stood at 63.2% of traded volume, against a 20-day average of 60.2%.
DIVI S LABORATORIES announcements: results, concalls, ratings, M&A.
Filings DIVI S LABORATORIES sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
DIVI S LABORATORIES files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 89 documents below.
Shareholders meeting
Divi's Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 10, 2026. Further, the company…
Analysts/Institutional Investor Meet/Con. Call Updates
Divi's Laboratories Limited has informed the Exchange about Transcript
Copy of Newspaper Publication
Divi's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Divi's Laboratories Limited has informed the Exchange about Link of Recording
Change in Management
Divi's Laboratories Limited has informed the Exchange about change in Senior Management.
DIVI S LABORATORIES dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue DIVI S LABORATORIES has declared, sequenced by announce and record date.
DIVI S LABORATORIES corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
DIVI S LABORATORIES insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in DIVI S LABORATORIES as reported to SEBI — buying and selling signals from the people who know the business best.
DIVI S LABORATORIES insider activity below tracks 19 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| A. Lakshmi | Insider | 25 Feb 2026 | buy | +500 | ₹32.07 L | ₹6,413.00 |
| A. Lakshmi | Insider | 25 Feb 2026 | buy | +500 | ₹32.07 L | ₹6,413.00 |
| A. Lakshmi | Insider | 25 Feb 2026 | buy | +500 | ₹32.07 L | ₹6,413.00 |
| A. Lakshmi | Insider | 25 Feb 2026 | buy | +500 | ₹32.07 L | ₹6,413.00 |
| A. Lakshmi | Insider | 25 Feb 2026 | buy | +500 | ₹32.07 L | ₹6,413.00 |
| A. Lakshmi | Insider | 25 Feb 2026 | buy | +500 | ₹32.07 L | ₹6,413.00 |
| K. Sridevi | Insider | 11 Jun 2025 | sell | −400 | ₹26.97 L | ₹6,741.86 |
| Yalavarthi Vamsi Krishna | Insider | 10 Jun 2025 | sell | −200 | ₹13.36 L | ₹6,678.00 |
| G.Kelitha | Insider | 27 May 2025 | sell | −150 | ₹10.49 L | ₹6,993.33 |
| Ch. Venu | Insider | 27 May 2025 | sell | −150 | ₹10.12 L | ₹6,745.00 |
About DIVI S LABORATORIES: business, sector, key facts.
What DIVI S LABORATORIES does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
DIVI S LABORATORIES operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: DIVISLAB, BSE: 532488.
Divi's Laboratories Limited is a leading Indian pharmaceutical company specializing in the manufacturing and sale of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceuticals. Their operations span a global reach, encompassing significant markets in India, North America, Asia, and Europe. A core element of their business involves the production of generic APIs, which are the fundamental building blocks for many pharmaceutical drugs. These are then supplied to other pharmaceutical companies for the formulation of their final products.
Beyond generic APIs, Divi's Laboratories also produces a wide range of intermediates. These are chemical compounds used in the synthesis of APIs, representing a crucial step in the pharmaceutical manufacturing process. Their expertise in both APIs and intermediates underscores their strong position within the pharmaceutical supply chain, providing both raw materials and partially processed components to a diverse customer base.
The company further expands its product portfolio into the nutraceutical sector. This involves manufacturing and distributing various vitamins and carotenoids, such as beta-carotene, astaxanthin, lycopene, and canthaxanthin. These products are primarily targeted towards the food, dietary supplement, and feed industries, showcasing Divi's diversification into related markets that capitalize on their chemical synthesis expertise.
A significant part of Divi's business model involves custom synthesis and contract manufacturing services. They offer their manufacturing capabilities to other companies seeking to produce specific APIs or intermediates, allowing them to leverage their advanced facilities and experienced personnel for a fee. This service component adds flexibility and scalability to their operations, enabling them to adapt to changing market demands and client needs.
Divi's Laboratories maintains a strong export focus, supplying their products to international markets. This global presence highlights their competitive capabilities and the international demand for their high-quality APIs, intermediates, and nutraceuticals. The company's long history and established reputation within the pharmaceutical industry contribute to its sustained success and ongoing growth.
Go deeper on DIVI S LABORATORIES
- DIVI S LABORATORIES resultsQuarter-by-quarter revenue, profit, EPS and margins for DIVI S LABORATORIES.
- DIVI S LABORATORIES dividendEvery dividend DIVI S LABORATORIES has declared, with ex-dates and yield.
- DIVI S LABORATORIES shareholdingPromoter, FII and DII holding in DIVI S LABORATORIES, quarter by quarter.
- DIVI S LABORATORIES financialsDIVI S LABORATORIES profit & loss, balance sheet and cash flow by year.
- DIVI S LABORATORIES technical analysisPivots, CPR and live indicator readings for DIVI S LABORATORIES.
- DIVI S LABORATORIES corporate actionsBonus issues, splits, rights and buybacks declared by DIVI S LABORATORIES.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about DIVI S LABORATORIES (DIVISLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of DIVI S LABORATORIES (DIVISLAB)?
The current share price of DIVI S LABORATORIES (DIVISLAB) is ₹9,100.00. Today, the stock has declined by ₹150.00 (1.62%), trading in a range of ₹9,100.00 to ₹9,269.00. The stock opened at ₹9,244.00 with a trading volume of 2,50,202 shares.
02Is DIVI S LABORATORIES stock a good investment for long-term?
DIVI S LABORATORIES can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2.42 L Cr., P/E ratio of 83.79, ROE of 15.6%, and ROCE of 15.79%. The dividend yield stands at 0.33%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of DIVI S LABORATORIES stock?
The 52-week high price of DIVI S LABORATORIES (DIVISLAB) is ₹9,467.00, while the 52-week low is ₹5,636.50. Currently trading at ₹9,100.00, the stock is 61.45% above its 52-week low and 3.88% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy DIVI S LABORATORIES stock at the current price?
Whether to buy DIVI S LABORATORIES stock at ₹9,100.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 83.79 and P/B ratio of 14.62. Today's performance shows a loss of 1.62%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of DIVI S LABORATORIES and when is the next dividend?
DIVI S LABORATORIES offers a dividend yield of 0.33%, which means for every ₹100 invested at the current price of ₹9,100.00, you can expect to receive approximately ₹0.33 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of DIVI S LABORATORIES?
DIVI S LABORATORIES's key financial metrics include: P/E Ratio: 83.79, P/B Ratio: 14.62, ROE: 15.6%, ROCE: 15.79%, Dividend Yield: 0.33%, EPS: ₹33.56, Book Value: ₹631.37, and Debt-to-Equity: 0. The company's market cap stands at ₹2.42 L Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is DIVI S LABORATORIES stock performing today in the market?
DIVI S LABORATORIES stock opened at ₹9,244.00 and is currently trading at ₹9,100.00, showing a decline of ₹150.00 (1.62%). The intraday high is ₹9,269.00 and low is ₹9,100.00. The trading volume stands at 2,50,202 shares, indicating moderate market participation today.
08What is the P/E ratio of DIVI S LABORATORIES and what does it indicate?
DIVI S LABORATORIES has a Price-to-Earnings (P/E) ratio of 83.79, which means investors are willing to pay 83.79 for every ₹1 of earnings. With an EPS of ₹33.56, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about DIVI S LABORATORIES (DIVISLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.